Correction: Blocking TIM3:Galectin-9 pathway enhances in vivo CAR19T cell function

CORRECTION

Falgàs A, Zanetti SR, Martínez-Moreno A , Panisello C, Romecin PA, Díez Alonso L, Álvarez Vallina L , Bueno C , Menéndez P. Blocking TIM3:Galectin-9 pathway enhances in vivo CAR19T cell function. Klin Padiatr 2023

DOI: 10.1055/s-0043-1768510

One-year relapse rates of leukemia patients treated with CD19-targeted CAR-T cells (CAR19T) are > 60 % partly due to CAR19T intrinsic mechanisms and their interaction with leukemic cells and their microenvironment. Here, we have comprehensively characterized the expression of inhibitory immune checkpoint receptors (ICRs) in T-cells, and their ligands in both leukemic cells and mesenchymal stromal cells (MSC) from bone marrow (BM) of pediatric and adult primary B-cell acute lymphoblastic leukemia (ALL) patients at diagnosis and relapse. Among all the ICRs-ligands analyzed, our results reveal a significant pregulation of the ICR TIM3 and its ligand Galectin-9 in T-cells and B-ALL/MSCs, respectively, during disease progression. The expression of TIM3 and Galectin-9 was signifcantly upregulated by CAR19Ts and CAR19T-resistant B-ALL cells, respectively, after in vitro cytotoxicity assays. Targeting TIM3:Galectin-9 axis may represent a promising co-adjuvant therapy in B-ALL patients treated with CAR19Ts.

Publication History

Article published online:
05 June 2024